Fabrice Giraudet1, Marie Selvy1,2, Nicolas Kerckhove1,3,4, Bruno Pereira5, Fantine Barreau6, Daniel Nguyen7, Jérôme Busserolles1, Aurélie Cabrespine6, Carine Chaleteix6, Martin Soubrier8,9, Jacques-Olivier Bay6,10, Richard Lemal6,10, David Balayssac11,12. 1. INSERM U1107, NEURO-DOL, UFR de Pharmacie, Université Clermont Auvergne, 28 Place Henri Dunant, 63000, Clermont-Ferrand, France. 2. Service de Chirurgie Digestive, CHU Clermont-Ferrand, 63000, Clermont-Ferrand, France. 3. Service de Pharmacologie, CHU Clermont-Ferrand, 63000, Clermont-Ferrand, France. 4. Institut Analgesia, Université Clermont Auvergne, 63000, Clermont-Ferrand, France. 5. Délégation à la recherche clinique et à l'innovation, CHU Clermont-Ferrand, 63000, Clermont-Ferrand, France. 6. Service d'Hématologie Clinique Adulte, CHU Clermont-Ferrand, 63000, Clermont-Ferrand, France. 7. College of Pharmacy, University of Oklahoma, Oklahoma City, Oklahoma, USA. 8. Service de Rhumatologie, CHU Clermont-Ferrand, 63000, Clermont-Ferrand, France. 9. UNH-UMR 1019, INRA, Université Clermont Auvergne, 63000, Clermont-Ferrand, France. 10. EA 7453 CHELTER, Université Clermont Auvergne, 63000, Clermont-Ferrand, France. 11. INSERM U1107, NEURO-DOL, UFR de Pharmacie, Université Clermont Auvergne, 28 Place Henri Dunant, 63000, Clermont-Ferrand, France. dbalayssac@chu-clermontferrand.fr. 12. Délégation à la recherche clinique et à l'innovation, CHU Clermont-Ferrand, 63000, Clermont-Ferrand, France. dbalayssac@chu-clermontferrand.fr.
Abstract
PURPOSE: Bortezomib is a neurotoxic drug used in multiple myeloma and responsible for chemotherapy-induced peripheral neuropathy (CIPN). In a previous cross-sectional study, CIPN prevalence was about 26.9% in 67 patients. A second data analysis was performed to explore the relation between CIPN and auditory difficulties. METHODS: Based on 66 multiple myeloma patients from a single center, auditory difficulties were assessed with a self-questionnaire and compared to sensory CIPN (QLQ-CIPN20 questionnaire), patients' characteristics and anticancer treatments. RESULTS: The prevalence of auditory difficulties was about 42.4% (95% CI [30.6-55.2]) of the 66 patients analyzed and was higher in patients with CIPN than without (82.4% vs. 28.6%, p < 0.001). Auditory difficulties were not related to the characteristics of patients and treatments. The severity of auditory difficulties were correlated to CIPN severity (spearman's coefficient: 0.49, p = 0.009). Odds-ratio of auditory difficulties (multivariable analysis adjusted for sensory CIPN, recreation or professional noise exposure, gender, age, and treatments) was significantly associated with CIPN (18.7, 95% CI [3.0-117.1], p = 0.002). CONCLUSION: This relation between CIPN and auditory difficulties raises concerns about hearing safety in multiple myeloma patients treated by bortezomib. TRIAL REGISTRATION NUMBER: NCT03344328.
PURPOSE: Bortezomib is a neurotoxic drug used in multiple myeloma and responsible for chemotherapy-induced peripheral neuropathy (CIPN). In a previous cross-sectional study, CIPN prevalence was about 26.9% in 67 patients. A second data analysis was performed to explore the relation between CIPN and auditory difficulties. METHODS: Based on 66 multiple myeloma patients from a single center, auditory difficulties were assessed with a self-questionnaire and compared to sensory CIPN (QLQ-CIPN20 questionnaire), patients' characteristics and anticancer treatments. RESULTS: The prevalence of auditory difficulties was about 42.4% (95% CI [30.6-55.2]) of the 66 patients analyzed and was higher in patients with CIPN than without (82.4% vs. 28.6%, p < 0.001). Auditory difficulties were not related to the characteristics of patients and treatments. The severity of auditory difficulties were correlated to CIPN severity (spearman's coefficient: 0.49, p = 0.009). Odds-ratio of auditory difficulties (multivariable analysis adjusted for sensory CIPN, recreation or professional noise exposure, gender, age, and treatments) was significantly associated with CIPN (18.7, 95% CI [3.0-117.1], p = 0.002). CONCLUSION: This relation between CIPN and auditory difficulties raises concerns about hearing safety in multiple myeloma patients treated by bortezomib. TRIAL REGISTRATION NUMBER: NCT03344328.
Authors: Marie Selvy; Nicolas Kerckhove; Bruno Pereira; Fantine Barreau; Daniel Nguyen; Jérôme Busserolles; Fabrice Giraudet; Aurélie Cabrespine; Carine Chaleteix; Martin Soubrier; Jacques-Olivier Bay; Richard Lemal; David Balayssac Journal: Front Pharmacol Date: 2021-04-22 Impact factor: 5.810
Authors: Nicolas Kerckhove; David Tougeron; Côme Lepage; Denis Pezet; Karine Le Malicot; Manon Pelkowski; Bruno Pereira; David Balayssac Journal: BMC Cancer Date: 2022-07-07 Impact factor: 4.638